04.28.14
New research on the omega-3 fatty acid Docosapentaenoic acid (DPA), is being unveiled this week during the Experimental Biology 2014 conference, which takes place from April 26-30, 2014 at the San Diego Convention Center.
Results of two separate studies will be presented by study co-author Amanda Pepper-Yowell, doctoral candidate at Texas Tech University, Department of Animal and Food Science. Both studies were sponsored by Omega Protein Corporation and conducted by Texas Tech University.
Results from the first study showed that purified EPA, DPA, DHA, and menhaden-oil-derived OmegaActiv Super DPA improved serum lipid profiles in mice. It also demonstrated that DPA decreases aortic plaque building, revealing its potential to help reduce atherosclerosis. The study was featured as part of a mini-symposium entitled “Medical Nutrition: Nutrition and Inflammation” held on Saturday, April 26.
Findings from the second study on anti-inflammatory effects of DPA in cell culture model will be highlighted during poster session 1034.16 on Tuesday, April 29 between 1:45 – 2:45 p.m. in the exhibit halls. This study showed molecular mechanisms of anti-inflammatory action of DPA, which is especially revealing since many chronic diseases including heart disease, atherosclerosis and obesity have an inflammatory component.
“Science focused specifically on DPA is on the rise and the scientific community is increasingly recognizing DPA’s therapeutic potential to work with EPA and DHA, and as a stand-alone fatty acid,” stated Dr. Mark E. Griffin, senior vice president of research and development at Omega Protein Corporation. “These two studies reveal DPA’s important role in health and both will be published in peer-reviewed journals in the immediate future.”
Results of two separate studies will be presented by study co-author Amanda Pepper-Yowell, doctoral candidate at Texas Tech University, Department of Animal and Food Science. Both studies were sponsored by Omega Protein Corporation and conducted by Texas Tech University.
Results from the first study showed that purified EPA, DPA, DHA, and menhaden-oil-derived OmegaActiv Super DPA improved serum lipid profiles in mice. It also demonstrated that DPA decreases aortic plaque building, revealing its potential to help reduce atherosclerosis. The study was featured as part of a mini-symposium entitled “Medical Nutrition: Nutrition and Inflammation” held on Saturday, April 26.
Findings from the second study on anti-inflammatory effects of DPA in cell culture model will be highlighted during poster session 1034.16 on Tuesday, April 29 between 1:45 – 2:45 p.m. in the exhibit halls. This study showed molecular mechanisms of anti-inflammatory action of DPA, which is especially revealing since many chronic diseases including heart disease, atherosclerosis and obesity have an inflammatory component.
“Science focused specifically on DPA is on the rise and the scientific community is increasingly recognizing DPA’s therapeutic potential to work with EPA and DHA, and as a stand-alone fatty acid,” stated Dr. Mark E. Griffin, senior vice president of research and development at Omega Protein Corporation. “These two studies reveal DPA’s important role in health and both will be published in peer-reviewed journals in the immediate future.”
